The U.S. Army Medical Research and Development Command (USAMRDC) selected the Army Liposome Formulation with QS21 (ALFQ) as one of the 2020 award recipients. ALFQ was developed by MHRP at Walter Reed Army Institute of Research (WRAIR) scientists and was awarded a patent in 2019. This Army-owned and developed adjuvant, ALFQ, has shown to be strongly potent as a vaccine adjuvant in preclinical studies.
This years’ award was jointly given to the Emerging Infectious Diseases Branch’s (EIDB) COVID vaccine, called Spike Ferritin Nanoparticle (SpFN). ALFQ is a component of the SpFN vaccine formulation. SpFN has shown promising results in preclinical studies and began Phase 1 clinical testing in April of 2021.
Congratulations to the team involved in ALFQ: